Baxalta inks deal to expand immuno-oncology business

(Reuters) - Drugmaker Baxalta Inc said on Monday it inked a deal with privately held Symphogen under which the companies will develop immuno-oncology drugs.

http://ift.tt/1RaYUy6

from Reuters: Health News
via animenewspro